Sanofi Pasteur has started a Phase 2 clinical study of a vaccine for primary prevention of Clostridium difficile infection. The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals.
ImmunoGen, Inc. announced the initiation of a randomized Phase 1/2 clinical trial to evaluate its proprietary product candidate, IMGN901, for first-line treatment of small-cell lung cancer (SCLC) in patients with extensive disease.
The major challenge for public health in the era of genomics is to generate the base of evidence necessary to demonstrate when use of genomic information in public health can improve health outcomes in a safe, effective and cost-effective manner.
The long, anxious wait for biopsy results could soon be over, thanks to a tissue-imaging technique developed at the University of Illinois.
A team of scientists from The Scripps Research Institute have uncovered a previously unknown regulatory mechanism in the body’s response to eliminate pathogens, such as bacteria and viruses.
Growing public demand for increased medical device and drug safety, as well as the need to develop medical products faster, is complicating the current regulatory approval process and relationship between the life sciences industry and its chief regulator.
Merck announced that its Board of Directors has elected Kenneth C. Frazier, currently Merck's president, as chief executive officer (CEO) and president, as well as a member of the board, effective January 1, 2011.
Playing online can mean more than killing time, thanks to a new game developed by a team of bioinformaticians at McGill University. Now, players can contribute in a fun way to genetic research.
CNS Therapeutics announced the FDA approval of Gablofen for use in the management of severe spasticity, giving healthcare providers a new, easy-to-administer and cost-effective intrathecal baclofen treatment option.
Syngene has introduced its new plug and play LED lighting modules, which fit all new G:BOX and Dyversity imagers. These modules make it easy and cost-effective to enable these imagers to detect single or multiple fluorescent DNA and proteins.
PerkinElmer, Inc. launched a panel of epigenetics-based detection reagents to enable high-throughput screening for new drug candidates. The assay kits can screen for epigenetic factors to assist researching diseases such as neurodegeneration and cancer.
Warwick Analytical Service has developed a fast and precise analytical service for organisations seeking to check the purity of their samples. Warwick Analytical Service is able to investigate and precisely measure the carbon, hydrogen, and nitrogen content of samples.
Sigma-Aldrich will use its CompoZr Zinc Finger Nuclease Technology to engineer various human stem cell lines that enable tracking of differentiation to specific mature cell types via fluorescent reporters, integrated directly into developmentally expressed genes.
About 30% of breast cancer patients have tumors that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes.
In the wake of devastating cholera outbreaks in refugee camps in earthquake-wracked Haiti, a group of leading experts have urged the United States to create an emergency stockpile of cholera vaccines for future humanitarian use.